Synonym
Dextrothyroxine sodium; Lisolipin; D-T4 sodium; Dextrotiroxina sodica; D-Thyroxine sodium; Detyroxin; dynothel;
IUPAC/Chemical Name
sodium (R)-2-amino-3-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)propanoate
InChi Key
YDTFRJLNMPSCFM-UTONKHPSSA-M
InChi Code
InChI=1S/C15H11I4NO4.Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;/h1-2,4-5,12,21H,3,20H2,(H,22,23);/q;+1/p-1/t12-;/m1./s1
SMILES Code
N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C([O-])=O.[Na+]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
798.85
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Evaluation of a hypocholesterolemic agent. Dextrothyroxine sodium (Choloxin). JAMA. 1969 May 12;208(6):1014-5. PubMed PMID: 5818672.
2: OWENS JC, NEELY WB, OWEN WR. Effect of sodium dextrothyroxine in patients receiving anticoagulants. Clin Med (Northfield). 1962 Oct;69:2283-4. PubMed PMID: 15445906.
3: OWEN WR, NEELY WB, OWENS JC. Effect of sodium dextrothyroxine on serum cholesterol in man. JAMA. 1961 Dec 9;178:1036-8. PubMed PMID: 14482904.
4: OWENS JC, NEELY WB, OWEN WR. Effect of sodium dextrothyroxine in patients receiving anticoagulants. N Engl J Med. 1962 Jan 11;266:76-9. PubMed PMID: 14482918.
5: PADILLA T, PADILLA T, PADILLA MA, PADILLA LT. [Clinical evaluation of sodium dextrothyroxine in hypercholesterolemic patients with angina pectoris]. Dia Med. 1962 Nov 22;34:2318-20. Spanish. PubMed PMID: 13940999.
6: Williams W, Warner W. Sodium dextrothyroxine as a hypocholesterolemic agent: retrospective analysis of 6000 patients. Manit Med Rev. 1968 Oct;48(8):374-6. PubMed PMID: 5724155.
7: LEW M, LEPP A, STARR P. Growth of weanling thyroidectomized rats on oral sodium dextrothyroxine. Endocrinology. 1963 Jan;72:160-1. PubMed PMID: 13930301.
8: Cooper EE, Michel AM. Cholesterol lowering measures with clinical observations on a thyroid analogue (Sodium Dextrothyroxine) NaDT4; 91 cases--4 year study. Med Times. 1965 Oct;93(10):1089-94. PubMed PMID: 5826769.
9: COHEN BM. SODIUM DEXTROTHYROXINE THERAPY FOR HYPERCHOLESTEROLEMIA. THREE YEARS OF ADMINISTRATION TO CARDIOVASCULAR SUBJECTS. Geriatrics. 1964 Aug;19:585-97. PubMed PMID: 14201416.
10: Bernstein A, Simon F, Schmitz TH, Warner WL. The effect of sodium dextrothyroxine on serum cholesterol and mortality rates in cardiac patients. Angiology. 1973 Apr;24(4):205-11. PubMed PMID: 4699516.
11: STARR P. Sodium dextrothyroxine and sodium levothyroxine. Results of their use in an athyreotic patient with angina pectoris and hypercholesteremia. JAMA. 1960 Aug 27;173:1934-5. PubMed PMID: 13833863.
12: WINKELMANN RK, KIERLAND RR, PERRY HO, MULLER SA. TREATMENT OF SCLERODERMA WITH SODIUM DEXTROTHYROXINE. Arch Dermatol. 1965 Jan;91:66-9. PubMed PMID: 14229604.
13: Garibaldi LR, Borrone C, de Martini I, Battistini E. Dextrothyroxine treatment of phosphorylase-kinase deficiency glycogenosis in four boys. Helv Paediatr Acta. 1978 Nov;33(4-5):435-41. PubMed PMID: 280544.
14: STARR P. FURTHER STUDIES ON THE THERAPEUTIC VALUE OF SODIUM DEXTROTHYROXINE. Clin Pharmacol Ther. 1964 Nov-Dec;5:728-36. PubMed PMID: 14226190.
15: SCHNEEBERG NG, HERMAN E, MENDUKE H, ALTSCHULER NK. Reduction of serum cholesterol by sodium dextrothyroxine in euthyroid subjects. Ann Intern Med. 1962 Feb;56:265-75. PubMed PMID: 13908890.
16: GOYETTE EM, SAAD A. The use of triparanol and sodium dextrothyroxine to lower serum cholesterol. Angiology. 1962 Feb;13:88-93. PubMed PMID: 13900898.
17: SCHNEEBERG NG, JOHNSON ME, FREDERICKS S, ANSARI A. EFFECT OF SODIUM DEXTROTHYROXINE ON THE THYROIDAL UPTAKE OF RADIOACTIVE IODINE IN HYPERTHYROID AND EUTHYROID SUBJECTS. J Clin Endocrinol Metab. 1965 Feb;25:286-7. PubMed PMID: 14264250.
18: COHEN BM. One year of sodium dextrothyroxine therapy for hypercholesterolemia. Angiology. 1962 Feb;13:69-74. PubMed PMID: 13880229.
19: Cohen BM. The therapy of hypercholesterolemia and six years' use of sodium dextrothyroxine: progress note. Curr Ther Res Clin Exp. 1967 Dec;9(12):618-22. PubMed PMID: 4965457.
20: Bechtol LD, Warner WL. Dextrothyroxine for lowering serum cholesterol. Analysis of data on 6066 patients. Angiology. 1969 Nov;20(10):565-79. PubMed PMID: 5347944.
